Fresenius Medical Care names Korangy CEO. Fresenius Medical Care stock gains 1.24 percent

Published on 10/09/2026 at 12:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Korangy starts on October 12, 2026 after a unanimous board vote. FMC stock stood at EUR 37.67 on October 9, 2026 versus EUR 37.21, plus 1.24 percent.

Key points in brief

Fresenius Medical Care appointed Shervin J. Korangy CEO effective October 12, 2026.
The leadership change follows second-quarter adjusted operating income of EUR 569 million, up 20 percent year over year.
FMC stock was trading at EUR 37.67 at Lang & Schwarz on October 9, 2026, up 1.24 percent versus the prior close.
The company will publish third-quarter 2026 results on November 3, 2026.

Pflegekraft betreut Patient an Dialysemaschine, schwarz-weiß Reportagestil — Eine eindringliche Schwarzweiß-Reportageaufnahme einer Pflegekraft beim Betreuen eines Patienten an einer Dialysemaschine – ein Motiv, das die menschliche Dimension der Dialyseversorgung wie bei Fresenius Medical Care AG (ISIN DE0005785802) verdeutlicht, Illustration mit AI erstellt.

Fresenius Medical Care (ISIN DE0005785802) was trading at EUR 37.67 at Lang & Schwarz on October 9, 2026 at 12:11 p.m. CEST, up 1.24 percent. The company named Shervin J. Korangy as CEO and Management Board chair effective October 12, 2026, according to Fresenius Medical Care in its October 7, 2026 release.

Three milestones from 2026

On August 3, 2026, Fresenius Medical Care reported second-quarter revenue of EUR 4,861 million, up from EUR 4,792 million, while adjusted operating income rose 20 percent to EUR 569 million, according to The Globe and Mail. On September 25, 2026, the company announced China portfolio changes and expected one-time costs of EUR 110 million in the third quarter, as Fresenius Medical Care reported. On October 7, 2026, the company announced Korangy's appointment.

What changes on October 12?

Korangy, 51, succeeds Helen Giza, who leaves after October 11, 2026. The company said the FME25+ transformation reduced its cost base by EUR 1.2 billion, giving the incoming CEO a more efficient platform for the next phase of growth, according to Fresenius Medical Care.

The next two dates are set

Korangy takes office on October 12, 2026, and Fresenius Medical Care will publish its third-quarter 2026 financial figures on November 3, 2026, according to the company's events calendar at Fresenius Medical Care.

FMC stock gains 1.24 percent

FMC stock was trading at EUR 37.67 at Lang & Schwarz on October 9, 2026 at 12:11 p.m. CEST, compared with the Lang & Schwarz prior close of EUR 37.21 on October 8, 2026. The further course of trading is shown by the continuously updated real-time quote of Fresenius Medical Care stock.